Skip to Content

The main clinical message from the Five-Year Analysis of Murano Study

In this MEdtalk Aron Kater present the Five-year follow-up data from the MURANO trial, showing that fixed-duration 2-year treatment with venetoclax-rituximab overall demonstrated durable response. The Murano study evaluates the benefit of fixed-duration combination therapy with venetoclax and rituximab compared with treatment with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
The new data demonstrates a sustained PFS and OS benefit in the group of patients treated with venetoclax and rituximab compared to bendamustine in combination with rituximab.

Arnon Kater

Get access to the article

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top